Medindia
Medindia LOGIN REGISTER
Advertisement

Naurex Inc. Reports Positive Top-Line Phase I Results for Its Novel Mechanism NMDA Receptor Modulator GLYX-13 in Treatment-Resistant Depression

Wednesday, February 10, 2010 General News
Advertisement
- Good Overall Safety with No Schizophrenia-Like Side Effects Seen in First-in-Human Clinical Trial of this Novel and Selective GFPA Mechanism Drug Candidate -

Contacts:

Corporate

Media

Naurex Inc.

GendeLLindheim BioCom Partners

Derek Small

Barbara Lindheim

Acting CEO

212 918-4650

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close